Mendes Maria, Sousa João José, Pais Alberto, Vitorino Carla
Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal.
Center for Neurosciences and Cell Biology (CNC), University of Coimbra, 3004-504 Coimbra, Portugal.
Pharmaceutics. 2018 Oct 9;10(4):181. doi: 10.3390/pharmaceutics10040181.
The poor prognosis and rapid recurrence of glioblastoma (GB) are associated to its fast-growing process and invasive nature, which make difficult the complete removal of the cancer infiltrated tissues. Additionally, GB heterogeneity within and between patients demands a patient-focused method of treatment. Thus, the implementation of nanotechnology is an attractive approach considering all anatomic issues of GB, since it will potentially improve brain drug distribution, due to the interaction between the blood⁻brain barrier and nanoparticles (NPs). In recent years, theranostic techniques have also been proposed and regarded as promising. NPs are advantageous for this application, due to their respective size, easy surface modification and versatility to integrate multiple functional components in one system. The design of nanoparticles focused on therapeutic and diagnostic applications has increased exponentially for the treatment of cancer. This dual approach helps to understand the location of the tumor tissue, the biodistribution of nanoparticles, the progress and efficacy of the treatment, and is highly useful for personalized medicine-based therapeutic interventions. To improve theranostic approaches, different active strategies can be used to modulate the surface of the nanotheranostic particle, including surface markers, proteins, drugs or genes, and take advantage of the characteristics of the microenvironment using stimuli responsive triggers. This review focuses on the different strategies to improve the GB treatment, describing some cell surface markers and their ligands, and reports some strategies, and their efficacy, used in the current research.
胶质母细胞瘤(GB)预后较差且复发迅速,这与其快速生长过程和侵袭性有关,这使得彻底清除癌浸润组织变得困难。此外,患者体内和患者之间的GB异质性需要以患者为中心的治疗方法。因此,考虑到GB的所有解剖学问题,纳米技术的应用是一种有吸引力的方法,因为血脑屏障与纳米颗粒(NPs)之间的相互作用可能会改善脑内药物分布。近年来,治疗诊断技术也被提出并被认为很有前景。NPs因其各自的尺寸、易于表面修饰以及能够在一个系统中整合多种功能成分而有利于此应用。专注于治疗和诊断应用的纳米颗粒设计在癌症治疗方面呈指数级增长。这种双重方法有助于了解肿瘤组织的位置、纳米颗粒的生物分布、治疗的进展和疗效,并且对基于个性化医疗的治疗干预非常有用。为了改进治疗诊断方法,可以使用不同的主动策略来调节纳米治疗诊断颗粒的表面,包括表面标志物、蛋白质、药物或基因,并利用刺激响应触发器利用微环境的特性。本综述重点关注改善GB治疗的不同策略,描述一些细胞表面标志物及其配体,并报告当前研究中使用的一些策略及其疗效。